<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03033745</url>
  </required_header>
  <id_info>
    <org_study_id>IgPro20_4004</org_study_id>
    <secondary_id>2016-003799-33</secondary_id>
    <nct_id>NCT03033745</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)</brief_title>
  <official_title>An Open-label Multicenter Study to Evaluate the Safety and Tolerability of Higher Infusion Parameters of Immune Globulin Subcutaneous (Human), 20% Liquid (Hizentra®) in Subjects With Primary Immunodeficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSL Behring</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSL Behring</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multicenter, open-label, parallel-arm, non-randomized study is designed to evaluate
      safety and tolerability of higher infusion parameters of IgPro20 in subjects with primary
      immunodeficiency (PID). A total of 45 subjects (including at least 14 [30%] pediatric
      subjects ≤ 17 years of age and at least 9 [20%] obese subjects with body mass index [BMI] of
      ≥30 kg/m2) with confirmed PID will be evaluated in the study. The study will include three
      cohorts of 15 subjects each as follows: i) Pump-Assisted Volume Cohort (weekly infusions),
      volume per injection site of 25 mL up to 50 mL, ii) Pump Assisted Flow Rate Cohort (weekly
      infusions), flow rate per injection site of 25 mL/hour up to 100 mL/hour, iii) Manual Push
      Flow Rate Cohort (2 to 7 infusions per week), flow rate per injection site of 25 to 30
      mL/hour up to 120 mL/hour (equivalent of approximately 0.5 mL/minute up to 2 mL/minute). Each
      cohort will test 3 infusion parameter levels (4 for the pump-assisted flow rate cohort),
      repeated at least 4 times over a duration of 12 weeks (16 weeks for the flow rate cohort).
      After 4 infusion weeks at each level, qualifying subjects (responders) will switch to the
      next infusion parameter level (eg, from 25 to 50 mL/h). During the study, the weekly dose
      will remain unchanged (as prescribed by treating physician, usually within 100-200 mg/kg per
      week range); only the respective infusion parameter under evaluation will change.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2017</start_date>
  <completion_date type="Anticipated">November 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Responders</measure>
    <time_frame>At the end of 4 weeks for each planned infusion volume/flow rate parameter level</time_frame>
    <description>A responder is a subject within the Pump-Assisted Cohorts that performs at least 3 out of 4 valid infusions at a certain infusion parameter level (weekly volumes per injection site of 25-50 mL; weekly flow rates per injection site of 25-100 mL/hour). Determination of a responder in the Manual Push Cohort is more complex due to the expected variable frequency of infusions per week for different subjects. A responder within the Manual Push Cohort is a subject that performs a minimum number of valid infusions (ie, 5-17) during 4 weeks corresponding to a certain flow rate level ([ie, 2-7 times per week], flow rates per injection site of 30-120 mL/hour). Valid infusions do not need to be consecutive, but each subject needs to adhere to the same schedule (number of infusions per week) throughout the study. An infusion parameter will be considered successful if at least one third of the subjects in the corresponding cohort are responders at that infusion parameter level.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of total adverse events (AEs)</measure>
    <time_frame>Up to 17 weeks.</time_frame>
    <description>The rate of total adverse events (AEs) per subject and per infusion by cohort and by each of the infusion parameter levels within the cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of local reactions</measure>
    <time_frame>Up to 17 weeks.</time_frame>
    <description>The rate of local reactions per subject and per infusion by cohort and by each of the infusion parameter levels within the cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to onset of local reactions</measure>
    <time_frame>Up to 17 weeks</time_frame>
    <description>The time to onset of local reactions per subject and per infusion by cohort and by each of the infusion parameter levels within the cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of local reactions</measure>
    <time_frame>Up to 17 weeks</time_frame>
    <description>Severity of local reactions per subject and per infusion by cohort and by each of the infusion parameter levels within the cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of local reactions</measure>
    <time_frame>Up to 17 weeks</time_frame>
    <description>Duration of local reactions per subject and per infusion by cohort and by each of the infusion parameter levels within the cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of infusions experiencing no severe local reactions</measure>
    <time_frame>Up to 17 weeks</time_frame>
    <description>For all cohorts: Tolerability of a certain infusion parameter, i.e. percentage of infusions per cohort by volume/flow rate subgroup experiencing no severe local reactions for each of the infusion parameter levels.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">51</enrollment>
  <condition>Primary Immunodeficiency</condition>
  <arm_group>
    <arm_group_label>IgPro20 (Pump-Assisted Volume Cohort)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weekly volumes per injection site of 25 mL up to 50 mL administered subcutaneously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IgPro20 (Pump Assisted Flow Rate Cohort)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weekly flow rates per injection site of 25 mL/hour up to 100 mL/hour administered subcutaneously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IgPro20 (Manual Push Flow Rate Cohort)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Frequent (ie, 2 to 7 times per week) flow rates per injection site of 25 to 30 mL/hour up to 120 mL/hour (equivalent of approximately 0.5 mL/minute up to 2 mL/minute) administered subcutaneously.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IgPro20</intervention_name>
    <description>A liquid formulation of normal human IgG at a concentration of 20% administered as a subcutaneous infusion at a dose prescribed by subject's physician prior to study entry.</description>
    <arm_group_label>IgPro20 (Pump-Assisted Volume Cohort)</arm_group_label>
    <arm_group_label>IgPro20 (Pump Assisted Flow Rate Cohort)</arm_group_label>
    <arm_group_label>IgPro20 (Manual Push Flow Rate Cohort)</arm_group_label>
    <other_name>Hizentra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female on stable dose of IgPro20 (Hizentra) therapy.

          -  Women of childbearing potential must be using and agree to continue using medically
             approved contraception (which must be discussed with the study doctor) and must have a
             negative pregnancy test at screening.

          -  Subjects with PID, eg, with a diagnosis of common variable immunodeficiency or
             X-linked agammaglobulinemia, as defined by the Pan American Group for Immune
             Deficiency and the European Society of Immune Deficiencies.

          -  With infusion parameters as specified below:

        Pump-Assisted Flow Rate Cohort subjects only

          -  Experience with pump-assisted infusions of IgPro20 at the tolerated flow rate of 25
             mL/h per injection site for at least 1 month prior to Day 1.

        Pump-Assisted Volume Cohort subjects only

          -  Total weekly IgPro20 dose of ≥ 50 mL (≥ 10 g).

          -  Experience with pump-assisted infusions of IgPro20 at tolerated volumes of 25
             mL/injection site for at least 1 month prior to Day 1.

        Manual Push Flow Rate Cohort subjects only

          -  Experience with frequent (2-7 times per week) infusions of IgPro20 at the tolerated
             flow rate of approximately 0.5 mL/min (equivalent of 25-30 mL/h) per injection site
             for at least 1 month prior to Day 1. The dose (volume) per injection site should not
             exceed 25 mL.

        Exclusion Criteria:

          -  Ongoing serious bacterial infections at the time of screening.

          -  Other significant medical conditions that could increase the risk to the subject.

          -  Females who are pregnant, breast feeding, or planning a pregnancy during the course
             study.

          -  Participation in a study with an Investigational Medicinal Product (IMP) other than
             IgPro20 within three months prior to enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Physician</last_name>
    <role>Study Director</role>
    <affiliation>CSL Behring</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Central Contact Clincal Trials Registration Coordinator</last_name>
    <phone>610-878-4000</phone>
    <email>clinicaltrials@cslbehring.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Research Center of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
      <email>clinicaltrials@CSLBehring.com</email>
    </contact>
    <investigator>
      <last_name>John Anderson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Solutions of Arizona</name>
      <address>
        <city>Litchfield Park</city>
        <state>Arizona</state>
        <zip>85340</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
      <email>clinicaltrials@CSLBehring.com</email>
    </contact>
    <investigator>
      <last_name>Connie Hsu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Southern Florida</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
      <email>clinicaltrials@cslbehring.com</email>
    </contact>
    <investigator>
      <last_name>Panida Sriaroon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgia Pollens Clinical Research Centers</name>
      <address>
        <city>Albany</city>
        <state>Georgia</state>
        <zip>31707</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
      <email>clinicaltrials@cslbehring.com</email>
    </contact>
    <investigator>
      <last_name>Tracy Bridges, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Long Island Jewish Medical Center</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
      <email>clinicaltrials@CSLBehring.com</email>
    </contact>
    <investigator>
      <last_name>Vincent Bonagura</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn Medical Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
      <email>clinicaltrials@cslbehring.com</email>
    </contact>
    <investigator>
      <last_name>Paul Maglione, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Research Rochester General Hospital</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
      <email>clinicaltrials@cslbehring.com</email>
    </contact>
    <investigator>
      <last_name>Shahzad Mustafa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Levine Children's Hospital</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
      <email>clinicaltrials@CSLBehring.com</email>
    </contact>
    <investigator>
      <last_name>Niraj Patel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University School of Medicine</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
      <email>clinicaltrials@CSLBehring.com</email>
    </contact>
    <investigator>
      <last_name>Patricia Lugar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
      <email>clinicaltrials@CSLBerhing.com</email>
    </contact>
    <investigator>
      <last_name>Juthaporn Cowan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill University</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4A3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
      <email>clinicaltrials@cslbehring.com</email>
    </contact>
    <investigator>
      <last_name>Donald Vinh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2017</study_first_submitted>
  <study_first_submitted_qc>January 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2017</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

